(Total Views: 560)
Posted On: 01/08/2020 6:57:28 PM
Post# of 155039
MAJOR $CYDY ARTICLE - $9.00 Price Target So metastatic cancer has been tackled and the stock is still in a daze because of what appears to be a warrant exercise. Shake it off and use as a buying opportunity. This article spells out everything that is needed.
Tweet this link (Cut and Paste)
Drug makers Merck, Johnson & Johnson, and GlaxoSmithKline dismantle Gilead in HIV drug race https://born2invest.com/articles/drug-makers-...UE.twitter
So how many people read this?
If we look at the figures, CytoDyn’s value proposition becomes a little clearer. If we look at a stock like Immunomedics, Inc. (IMMU) with a $4.5 billion market cap and a total available patient population of 22 thousand, then we can estimate that CytoDyn, with a patient population of around 170 thousand, could justify a valuation of around $9.00."
Tweet this link (Cut and Paste)
Drug makers Merck, Johnson & Johnson, and GlaxoSmithKline dismantle Gilead in HIV drug race https://born2invest.com/articles/drug-makers-...UE.twitter
So how many people read this?
If we look at the figures, CytoDyn’s value proposition becomes a little clearer. If we look at a stock like Immunomedics, Inc. (IMMU) with a $4.5 billion market cap and a total available patient population of 22 thousand, then we can estimate that CytoDyn, with a patient population of around 170 thousand, could justify a valuation of around $9.00."
(1)
(0)
